Bladder cancer – progress in the treatment of non‑invasive stages

02/2021

MUDr. Jana Katolická, Ph.D.

Onkologicko-chirurgické oddělení LF MU a FN u sv. Anny, Brno

SUMMARY

Non-invasive urothelial carcinoma of the bladder is commonly treated with topical therapy. Intravesical administration of the BCG vaccine has shown significant benefit in medium and high-risk patients. A new treatment option for non-BCG-responsive tumors is pembrolizumab.

Key words

non-invasive urothelial carcinoma of the bladder, BCG vaccine, pembrolizumab